Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Therapeutic Advances in Medical OncologyOpen Access

Time to progression is a simple and robust prognostic factor for survival in relapsed or refractory diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

CCChieh‐Lung ChengNational Taiwan University HospitalTHTai‐Chung HuangNational Taiwan University HospitalJLJun LiangArmy Medical University

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows that time to progression predicts survival in relapsed/refractory DLBCL, suggesting novel therapies may be needed for high-risk patients.

Key Points

  • Patients with time to progression under 12 months have significantly lower survival rates.
  • Two-year overall survival ranges from 35.4% to 74.4% based on time to progression after R-CHOP.
  • Cox proportional hazards regression was used to analyze clinical data for relapsed/refractory DLBCL.
  • Identifying time to progression as a robust prognostic factor highlights the need for innovative treatment strategies.

Cite This Study

Cheng et al. (2025) studied this question.

synapsesocial.com/papers/693624ba4fa91c937236c90chttps://doi.org/10.1177/17588359251396884
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The <scp>STRIDER</scp> study2024 · 12 citations
  2. 2Real‐world patient characteristics, treatment patterns, and treatment outcomes of patients with diffuse large B‐cell lymphoma by line of therapy2024 · 18 citations
  3. 3Frequency of Complete Remission With R-CHOP Therapy in Patients With Diffuse Large B Cell Lymphoma2024 · 1 citations
  4. 4A simple, 3-factor pre-treatment score (Toranomon Prognostic Score) robustly stratifies progression risk in patients with relapsed/refractory large B-cell lymphoma receiving commercial CAR T-cell therapy: A real-world analysis2025
  5. 5Integrating genomic features for prognosis in Chinese patients with diffuse large B-cell lymphoma following R-CHOP therapy2026 · 1 citations